13F-HR filed by SAMSARA BIOCAPITAL, LLC
SAMSARA BIOCAPITAL, LLC filed this 13F-HR for the quarter ended 2026-03-31, filed 2026-05-15, with 22 holding rows worth $1,029,103,106.
- Accession
- 0001744967-26-000005
- Filer
- CIK 1744967
- Filed
- 2026-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2026
A holdings report, 22 entries on the cover page, a total value of $1,029,103,106 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,029,103,106 with VALUE read as dollars as filed, 13F file number 028-19375. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| SCHOLAR ROCK HLDG CORP | 80706P103 | COM | 6,897,652 | $339,088,572 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 5,871,018 | $159,045,878 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 6,345,219 | $139,785,175 | dollars as filed | |
| SEPTERNA INC COM | 81734D104 | Stock | 3,149,128 | $75,673,546 | dollars as filed | |
| KALARIS THERAPEUTICS INC | 482929106 | COM | 12,948,081 | $74,710,427 | dollars as filed | |
| SPYGLASS PHARMA INC | 85220G109 | COMMON STOCK | 2,109,953 | $54,668,882 | dollars as filed | |
| NEUROGENE INC | 64135M105 | COMMON STOCK | 1,717,127 | $34,617,280 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 5,194,805 | $28,831,168 | dollars as filed | |
| SUTRO BIOPHARMA INC | 869367201 | COMMON STOCK | 1,062,872 | $26,476,142 | dollars as filed | |
| JADE BIOSCIENCES INC | 008064206 | COM NEW | 968,798 | $13,611,612 | dollars as filed | |
| VTV THERAPEUTICS INC | 918385204 | CL A NEW | 298,496 | $11,838,351 | dollars as filed | |
| AQUESTIVE THERAPEUTICS INC COM | 03843E104 | Stock | 2,500,000 | $10,375,000 | dollars as filed | |
| X4 PHARMACEUTICALS INC | 98420X202 | COMMON STOCK | 1,832,566 | $7,568,498 | dollars as filed | |
| NKARTA INC | 65487U108 | COMMON STOCK | 3,507,666 | $7,401,175 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 60,873 | $6,989,438 | dollars as filed | |
| UPSTREAM BIO INC | 91678A107 | COMMON STOCK | 736,047 | $6,624,423 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 56,581 | $6,300,294 | dollars as filed | |
| AGOMAB THERAPEUTICS NV | 00860C102 | SPONSORED ADS | 600,000 | $6,294,000 | dollars as filed | |
| RANI THERAPEUTICS HLDGS INC | 753018100 | CMN | 8,500,000 | $6,245,800 | dollars as filed | |
| COHERUS ONCOLOGY INC | 19249H103 | COM | 3,428,571 | $5,794,285 | dollars as filed | |
| PALVELLA THERAPEUTICS INC | 697947109 | COMMON STOCK | 38,432 | $4,790,549 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 7,222,559 | $2,372,611 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001744967-26-000005 | this filing | 2026-05-15 | acceptance time not in the bulk data set |